ALDX Aldeyra Therapeutics, Inc.
Healthcare$1.78+14.84%ClosedMarket Cap: $107.4M
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
0.00
P/S
0.00
EV/EBITDA
1919339.22
DCF Value
$0.91
FCF Yield
-24.2%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-0.0%
ROA
0.0%
ROIC
0.0%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $0.00 | -Infinity% | $-3.5M | $-3.5M | $— | — |
| Q4 null | $0.00 | NaN% | $-6.7M | $-6.5M | $— | — |
| FY null | $0.00 | NaN% | $-35.3M | $-33.8M | $— | — |
| Q3 null | $0.00 | NaN% | $-8.0M | $-7.7M | $— | — |
| Q2 null | $0.00 | NaN% | $-10.2M | $-9.8M | $— | — |
| Q1 null | $0.00 | NaN% | $-10.4M | $-9.9M | $— | — |
| Q4 null | $0.00 | NaN% | $-16.6M | $-15.8M | $— | — |
| FY null | $0.00 | NaN% | $-60.1M | $-55.9M | $— | — |
| Q3 null | $0.00 | NaN% | $-16.1M | $-15.1M | $— | — |
| Q2 null | $0.00 | NaN% | $-18.0M | $-16.8M | $— | — |
| Q1 null | $0.00 | NaN% | $-9.4M | $-8.1M | $— | — |
| Q4 2023 | $0.00 | -Infinity% | $-6.1M | $-4.8M | $-0.08 | — |